Abstract
BackgroundThe WHO recommends use of the RTS,S/AS01E(RTS,S) malaria vaccine for young children living in areas of moderate to highPlasmodium falciparummalaria transmission and suggests countries consider seasonal vaccination in areas with highly seasonal malaria. Seasonal vaccination is uncommon and may require adaptations with potential cost consequences. This study prospectively estimates cost of seasonal malaria vaccine delivery in Mali and Burkina Faso.MethodsThree scenarios for seasonal vaccine delivery are costed (1) mass campaign only, (2) routine Expanded Programme on Immunisation (EPI) and (3) mixed delivery (mass campaign and routine EPI)), from the government’s perspective. Resource use data are informed by previous new vaccine introductions, supplemented with primary data from a sample of health facilities and administrative units.FindingsAt an assumed vaccine price of US $5 per dose, the economic cost per dose administered ranges between $7.73 and $8.68 (mass campaign), $7.04 and $7.38 (routine EPI) and $7.26 and $7.93 (mixed delivery). Excluding commodities, the cost ranges between $1.17 and $2.12 (mass campaign), $0.48 and $0.82 (routine EPI) and $0.70 and $1.37 (mixed delivery). The financial non-commodity cost per dose administered ranges between $0.99 and $1.99 (mass campaign), $0.39 and $0.76 (routine EPI) and $0.58 and $1.28 (mixed delivery). Excluding commodity costs, service delivery is the main cost driver under the mass campaign scenario, accounting for 36% to 55% of the financial cost. Service delivery accounts for 2%–8% and 12%–23% of the total financial cost under routine EPI and mixed delivery scenarios, respectively.ConclusionVaccine delivery using the mass campaign approach is most costly followed by mixed delivery and routine EPI delivery approaches, in both countries. Our cost estimates provide useful insights for decisions regarding delivery approaches, as countries plan the malaria vaccine rollout.
Funder
Bill and Melinda Gates Foundation
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference18 articles.
1. World Health Organization (WHO) . World malaria report 2021. 2021. Available: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021
2. Seasonal malaria vaccination with or without seasonal malaria chemoprevention;Chandramohan;N Engl J Med,2021
3. World Health Organization . Malaria vaccine: WHO position paper – march 2022. weekly epidemiological record. 2022. Available: https://www.who.int/publications/i/item/who-wer9709-61%E2%80%9380
4. World Health Organization (WHO) . Full evidence report on the RTS,S/AS01 malaria vaccine. 2021. Available: https://cdn.who.int/media/docs/default-source/immunization/mvip/full-evidence-report-on-the-rtss-as01-malaria-vaccine-for-sage-mpag-%28sept2021%29.pdf
5. Baral R , Levin A , Odero C , et al . Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries. PLoS ONE 2021;16:e0244995. doi:10.1371/journal.pone.0244995
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献